GlassScriptPhysician profile
Jeffrey A Passer
NPI 1326057571
$145,818.33
in general payments reported to CMS, 2019-2025
23 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $9,243 · 2021: $26K · 2022: $31K · 2023: $19K · 2024: $30K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $78K · Food and Beverage: $30.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $78,270.00 |
| Food and Beverage | $30.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $143,174.23 | 2020-2025 | |
| Amgen INC. | $1,101.47 | 2019-2021 | |
| Janssen Biotech, INC. | $248.99 | 2019-2021 | |
| Abbvie INC. | $225.46 | 2019-2021 | |
| Lilly USA, LLC | $173.34 | 2019-2021 | |
| Celgene Corporation | $157.86 | 2019 | |
| Ucb, INC. | $143.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $119.27 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $88.30 | 2021 | |
| Antares Pharma, INC. | $64.61 | 2019 | |
| Pfizer INC. | $56.27 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $46.97 | 2021-2023 | Lupkynis |
| Arbor Pharmaceuticals, INC. | $44.02 | 2020-2021 | |
| Genentech USA, INC. | $32.19 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $21.39 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.21 | 2019 | |
| Boston Scientific Corporation | $19.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.68 | 2019 | |
| Tolmar, INC. | $14.61 | 2025 | Jatenzo |
| Actelion Pharmaceuticals US, INC. | $12.31 | 2021 | |
| Merck Sharp & Dohme LLC | $11.84 | 2019 | |
| Eisai INC. | $11.72 | 2020 | |
| Pacira Therapeutics, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Passer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.